


IFW



DOCKET 13510CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: LEAKE *et al.* Examiner: BOWMAN, Amy Hudson
Serial No.: 10/613077 Group Art Unit: 1635
Filed: July 1, 2003
For: Stabilized Polynucleotides for Use in RNA Interference
Customer No.: 23719

Kalow & Springut LLP
488 Madison Avenue, 19th Floor
New York, New York 10022

April 8, 2005

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, Applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO-1449 (copies of cited references are enclosed). As to any reference supplied, Applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserves the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with Applicants' duty to disclose all information of which they are aware and believe relevant to the examination of the above-identified application, Applicants believe that their invention is patentable.

Certificate of Mailing Under 37 C.F.R. 1.8


I hereby certify that this correspondence is being deposited on the date shown below with the United States Postal Service as first class mail with sufficient postage in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


(Signature)

Angel Matos
(Printed Name of Person Signing Certificate)

4/8/05
(Date)

BEST AVAILABLE COPY



I. U.S. PATENT DOCUMENTS

| <u>Patent No.</u> | <u>Date Issued</u> | <u>Title</u> |
|--|---------------------------|---|
| 5,998,203 MATULIC-ADAMIC <i>et al.</i> | December 7, 1999 | Enzymatic Nucleic Acids Containing 5'-and/or 3'-Cap Structures |
| 6,111,086 SCARINGE | August 29, 2000 | Orthoester Protecting Groups |
| 2004/0009938 A1 MANOHARAN <i>et al.</i> | January 15, 2004 | Methods of Enhancing Renal Uptake of Oligonucleotides |
| 2005/0020525 A1 McSWIGGEN <i>et al.</i> | January 27, 2005 | RNA Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (SINA) |

II. FOREIGN PATENT DOCUMENTS

| <u>Publication No.</u> | <u>Country</u> | <u>Publication Date</u> |
|-------------------------------|-----------------------|--------------------------------|
| WO 02/094185 | WO | 28 November 2002 |

III. NON PATENT PUBLICATIONS

AMARZGUIOUI *et al.*, Tolerance for mutations and chemical modifications in siRNA, 2003, Nucleic Acids Research, Vol. 31, No. 2, pages 589-595.

PARRISH *et al.*, Functional Anatomy of a dsRNA Trigger: Differential Requirement for the Two Trigger Strands in RNA Interference, November 2000, Molecular Cell, Vol. 6, pages 1077-1087.

ELBASHIR *et al.*, RNA interference is mediated by 21- and 22-nucleotide RNAs, January 2001, Genes & Development, Vol. 15, pages 188-200.

LETSINGER *et al.*, Cholesteryl-conjugated oligonucleotides: Synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture, September 1989, Proc. Natl. Acad. Sci. Vol. 86, pages 6553-6556.

Applicant: LEAKE *et al.*
Serial No.: 10/613077
Filed: July 1, 2003
Supplemental Information Disclosure Statement
April 8, 2005
Page 3 of 3

BEST AVAILABLE COPY

Because no action has been taken on the merits, Applicants submit that no fee is due at this time. However, if a fee is deemed necessary, please charge Deposit Account No. 11-0171.

Respectfully submitted,



Tor Smeland
Registration No.: 43,131
Attorney for Applicant

Kalow & Springut LLP
(212) 813-1600

BEST AVAILABLE COPY

PTO/SB/08B (08-03)

Approved for use through 07/31/2006: OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|--------------------------|---------------------|------------------------|----------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 10/613077 | | |
| | | Filing Date | July 1, 2003 | | |
| | | First Named Inventor | LEAKE <i>et al.</i> | | |
| | | Art Unit | 1635 | | |
| | | Examiner Name | BOWMAN, Amy Hudson | | |
| Sheet | 2 | of | 2 | Attorney Docket Number | 13510CIP |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | AMARZGUIOU <i>et al.</i> , Tolerance for mutations and chemical modifications in siRNA, 2003, Nucleic Acids Research, Vol 31, No. 2, pages 589-595. | |
| | | PARRISH <i>et al.</i> , Functional Anatomy of a dsRNA Trigger: Differential Requirement for the Two Trigger Strands in RNA Interference, November 2000, Molecular Cell, Vol. 6, pages 1077 - 1087. | |
| | | ELBASHIR <i>et al.</i> , RNA interference is mediated by 21 - and 22- nucleotide RNAs, January 2001, Genes & Development, Vol. 15, pages 188-200. | |
| | | LETSINGER <i>et al.</i> , Cholesteryl-conjugated oligonucleotides: Synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture, September 1989, Proc. Natl. Acad. Sci. Vol. 86, pages 6553-6556 | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.